Market Cap (In EUR)
611 Million
Revenue (In EUR)
53.75 Million
Net Income (In EUR)
-260.16 Million
Avg. Volume
20.56 Thousand
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.056-4.808
- PE
- -
- EPS
- -
- Beta Value
- 2.611
- ISIN
- NL0015436031
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Alexander Zehnder M.B.A., M.D.
- Employee Count
- -
- Website
- https://www.curevac.com
- Ipo Date
- 2020-08-14
- Details
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
More Stocks
-
AREA
-
BONXFBonterra Resources Inc.
BONXF
-
0H9NAECOM
0H9N
-
IVN
-
LAMBODHARALambodhara Textiles Limited
LAMBODHARA
-
IFPJFInforma plc
IFPJF
-
CDDRF
-
SASKENSasken Technologies Limited
SASKEN